Rare Hematology News
Advertisement
Disease Profile
Liposarcoma
Prevalence estimates on Rare Medical Network websites are calculated based on data available from numerous sources, including US and European government statistics, the NIH, Orphanet, and published epidemiologic studies. Rare disease population data is recognized to be highly variable, and based on a wide variety of source data and methodologies, so the prevalence data on this site should be assumed to be estimated and cannot be considered to be absolutely correct.
Unknown
Age of onset
All ages
ICD-10
C49.9
Inheritance
Autosomal dominant A pathogenic variant in only one gene copy in each cell is sufficient to cause an autosomal dominant disease.
Autosomal recessive Pathogenic variants in both copies of each gene of the chromosome are needed to cause an autosomal recessive disease and observe the mutant phenotype.
X-linked
dominant X-linked dominant inheritance, sometimes referred to as X-linked dominance, is a mode of genetic inheritance by which a dominant gene is carried on the X chromosome.
dominant X-linked dominant inheritance, sometimes referred to as X-linked dominance, is a mode of genetic inheritance by which a dominant gene is carried on the X chromosome.
X-linked
recessive Pathogenic variants in both copies of a gene on the X chromosome cause an X-linked recessive disorder.
recessive Pathogenic variants in both copies of a gene on the X chromosome cause an X-linked recessive disorder.
Mitochondrial or multigenic Mitochondrial genetic disorders can be caused by changes (mutations) in either the mitochondrial DNA or nuclear DNA that lead to dysfunction of the mitochondria and inadequate production of energy.
Multigenic or multifactor Inheritance involving many factors, of which at least one is genetic but none is of overwhelming importance, as in the causation of a disease by multiple genetic and environmental factors.
Not applicable
Categories
Rare Cancers
Summary
Liposarcoma is a
Treatment
Sometimes radiation therapy or chemotherapy may be done prior to surgery to shrink the tumor; this may increase the chance of removing the whole tumor during surgery while limiting the impact to other organs. [3] [4]
FDA-Approved Treatments
The medication(s) listed below have been approved by the Food and Drug Administration (FDA) as orphan products for treatment of this condition. Learn more orphan products.
- Eribulin mesylate(Brand name: Halaven) Manufactured by Eisai, Inc.
FDA-approved indication: Treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracyclne-containing regimen
National Library of Medicine Drug Information Portal
Medline Plus Health Information - Trabectedin(Brand name: Yondelis) Manufactured by Janssen Research & Development, LLC
FDA-approved indication: For the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen.
National Library of Medicine Drug Information Portal
Medline Plus Health Information
Organizations
Support and advocacy groups can help you connect with other patients and families, and they can provide valuable services. Many develop patient-centered information and are the driving force behind research for better treatments and possible cures. They can direct you to research, resources, and services. Many organizations also have experts who serve as medical advisors or provide lists of doctors/clinics. Visit the group’s website or contact them to learn about the services they offer. Inclusion on this list is not an endorsement by GARD.
Organizations Supporting this Disease
-
Sarcoma Alliance for Research through Collaboration (SARC)
24 Frank Lloyd Wright Drive
Lobby A, Suite 3100
Ann Arbor, MI 48105
Telephone: +1-734-930-7600
Fax: +1-734-930-7557
E-mail: [email protected]
Website: https://sarctrials.org -
The Liddy Shriver Sarcoma Initiative
17 Bethea Drive
Ossining, NY 10562-1620
Telephone: 914-762-3251
Website: https://sarcomahelp.org/
Learn more
These resources provide more information about this condition or associated symptoms. The in-depth resources contain medical and scientific language that may be hard to understand. You may want to review these resources with a medical professional.
In-Depth Information
- Medscape Reference provides information on this topic. You may need to register to view the medical textbook, but registration is free.
- The Monarch Initiative brings together data about this condition from humans and other species to help physicians and biomedical researchers. Monarch’s tools are designed to make it easier to compare the signs and symptoms (phenotypes) of different diseases and discover common features. This initiative is a collaboration between several academic institutions across the world and is funded by the National Institutes of Health. Visit the website to explore the biology of this condition.
References
- Sarcoma Adult Soft Tissue Cancer. American Cancer Society. July 6, 2010; https://www.cancer.org/Cancer/Sarcoma-AdultSoftTissueCancer/DetailedGuide/sarcoma-adult-soft-tissue-cancer-soft-tissue-sarcoma. Accessed 2/14/2011.
- Schwartz RA. Liposarcoma. Medscape Reference. February, 2016; https://emedicine.medscape.com/article/1102007-overview.
- Adult Soft Tissue Sarcoma Treatment Health Professional Version. National Cancer Institute. January 24, 2011; https://www.cancer.gov/cancertopics/pdq/treatment/adult-soft-tissue-sarcoma/HealthProfessional. Accessed 2/14/2011.
- Soft Tissue Sarcoma. National Comprehensive Cancer Network. February 1, 2011; https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf. Accessed 2/14/2011.
Rare Hematology News